Advertisement

Hypertension in Diabetics

  • Ronald A. Codario
Chapter
Part of the Current Clinical Practice book series (CCP)

Abstract

The worldwide prevalence of hypertension is expected to increase from approximately 1 billion individuals in 2000 to over 1.5 billion in 2025 and is currently the most frequent medical diagnosis in the USA [1]. Not only is hypertension a powerful risk factor for cardiovascular disease, doubling the risk of mortality from coronary heart disease and stroke for every 20 mmHg increase in systolic blood pressure and 10 mmHg increase in diastolic pressure, but also is closely linked to the risk of developing type-2 diabetes.

Key Words

Hypertension Hypertensive diabetic Combination Therapy Cardiovascular disease Osaka Health Survey 

References

  1. 1.
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States 1988–2000. JAMA 2003;290:199–206.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayashi T, Tsumura K, Suematsu C, Okada K, Fujii S, Endo G. The Osaka Health Survey. Ann Intern Med 1999;131(1):21–26.PubMedCrossRefGoogle Scholar
  3. 3.
    US Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. Ann Intern Med. 2004;140:569–572.CrossRefGoogle Scholar
  4. 4.
    United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes. BMJ 1998;317:703–713.CrossRefGoogle Scholar
  5. 5.
    Staessen JA, Fagard R, Thijs L. Randomised double blind comparison of placebo active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757–764.PubMedCrossRefGoogle Scholar
  6. 6.
    Tuomilehto J, Lindstrom J, Eriksson JG. Prevention of type-2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.PubMedCrossRefGoogle Scholar
  7. 7.
    Gifford RW. A missed opportunity; our failure to control hypertension optimally. J Clin Hypertens 2000;2:21–24.Google Scholar
  8. 8.
    DeSimone G, Roman MJ, Alderman MH. High pulse pressure as a marker for preclinical cardiovascular disease. Hypertension 2005;45:575–579.CrossRefGoogle Scholar
  9. 9.
    United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703–771CrossRefGoogle Scholar
  10. 10.
    Van Itllie TB. Health implications of overweight and obesity in the United States. Ann Intern Med 1985;103(6):983–988.CrossRefGoogle Scholar
  11. 11.
    Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension; principal results of the Hypertension Optimum (HOT) trial. Lancet 1998;351:1755–1762.PubMedCrossRefGoogle Scholar
  12. 12.
    Hansson L, Zanchetti A, et al. for the HOT Study Group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension. Lancet 1998;351:1755–1762.Google Scholar
  13. 13.
    Adler A, Stratton I, Neill H. Association of systolic blood pressure with macrovascular and microvascular complications of type-2 diabetes (UKPDS-36). BMJ 2000;321:412–419.PubMedCrossRefGoogle Scholar
  14. 14.
    Curb JD, Pressel SL, et al. Effect of diuretic based antihypertensive treatment on cardiovascular risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886–1892.PubMedCrossRefGoogle Scholar
  15. 15.
    Basile J, Lackland D, et al. A statewide primary care approach to cardiovascular risk factor control in high risk diabetic and non diabetic patients with hypertension. J Clin Hypertens (Greenwich) 2004;6(1):18–25.CrossRefGoogle Scholar
  16. 16.
    Ravid M, Lang R. et al. Long term renoprotective effect of angiotensin-converting enzyme inhibition on insulin dependent diabetes mellitus. Arch Intern Med 1996;156:286–289.PubMedCrossRefGoogle Scholar
  17. 17.
    Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Keplinsky E. The bezafibrate infarction prevention (BIP) trial. Am J Cardiol 1993;71(11):909–915.PubMedCrossRefGoogle Scholar
  18. 18.
    American Diabetes Association. Treatment of hypertension in adults with diabetes, Diabetes Care 2002;199–201:213–229.Google Scholar
  19. 19.
    American Association of Clinical Endocrinologists Ad Hoc Task Force for Standardized Production of Clinical Practice guidelines. AACE protocol for standardized production of clinical practice guidelines. Endocr Pract. 2004;10;353–361.CrossRefGoogle Scholar
  20. 20.
    Lindholm L, Persson M, Alaupovic P,Carlberg V, Svensson A, Samuelsson O. The Antihypertesnive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE) study. Journal of Hypertension 2003;21(8):1563–1574.PubMedCrossRefGoogle Scholar
  21. 21.
    Poole-Wilson P, Swedberg K, Cleland J, Lenarda A, Hanrath P, Komajda M. The Carvedilol or Metoprolol European (COMET) Trial. Lancet 2003;362(9377):7–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Bakris Gl, Fonseca V, Katholi RE. Metabolic effects of carvedilol vs. metoprolol in patients with type-2 diabetes mellitus and hypertension. GEMINI trial. JAMA 2004;292:2227–2236.CrossRefGoogle Scholar
  23. 23.
    Giugliano D, Acampora R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. Ann Intern Med 1997;126:955–959.PubMedCrossRefGoogle Scholar
  24. 24.
    Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. (ABCD Trial). N Engl J Med 1998;338:645–652.PubMedCrossRefGoogle Scholar
  25. 25.
    Tatti P, Pahor M, et al. Outcome results of the fosinopril versus amlodipine cardiovascular randomized events trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. Diabetes Care 1998;21:597–603.PubMedCrossRefGoogle Scholar
  26. 26.
    Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;154:2413–2446.Google Scholar
  27. 27.
    Hansson L, Lund-Johansen P, Hedner T. Randomized trial of effects of calcium antagonists compared with diuretics and beta blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:366–372.CrossRefGoogle Scholar
  28. 28.
    Brown MJ, Palmer CR, Castaigne A. Morbidity and mortality in patients randomized to double blind treatment with a long acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in Hypertension treatment (INSIGHT). Lancet 2000;356:366–372.PubMedCrossRefGoogle Scholar
  29. 29.
    Walker WG, Herman J, et al. Elevated blood pressure and angiotensin II are associated with accelerated loss of renal function in diabetic nephropathy. Trans Am Clin Climatol Assoc 1985;97:94–104.Google Scholar
  30. 30.
    Brenner BM, Cooper ME, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.PubMedCrossRefGoogle Scholar
  31. 31.
    Bakris GL, Williams M, et al. Special Report: Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J kidney Dis. 2000;36:661.Google Scholar
  32. 32.
    Oh B, Mitchell J, Herron J, Chung J. Khan M. Aliskiren, an oral rennin inhibitor, provides dose dependent efficacy and sustained 24 hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49(11):1157–1163.PubMedCrossRefGoogle Scholar
  33. 33.
    Duprez D. Aliskiren, the next innovation in the rennin-angiotensin-aldosteronesystem blockade. Aging Health 2009;3(5):269–279.CrossRefGoogle Scholar
  34. 34.
    Tuomilehto J, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Lancet 1997;6:357–364.Google Scholar
  35. 35.
    Estacio, RO, Jeffers BW, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–B64.PubMedGoogle Scholar
  36. 36.
    Materson BJ, Reda DJ, Cushman WC. Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of veterans Affairs Cooperative Study group on Antihypertensive Agents. N Engl J Med 1993;328:914–921.PubMedCrossRefGoogle Scholar
  37. 37.
    Adler AI, Stratton IM, et al. Association of systolic blood pressure with marovascular and microvascular complications of type 2 diabetes. BMJ 2000; 321(7258):405–412.Google Scholar
  38. 38.
    Laffel LMB, McGill JB, et al. The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497–540.PubMedCrossRefGoogle Scholar
  39. 39.
    Lewis EJ, Hunsiker LG, et al. Renoprotective effect of the angiotensin receptor blockers irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.PubMedCrossRefGoogle Scholar
  40. 40.
    Reid CM, Ryan P, Nelson M. General practitioner participation in the second Australian National Blood Pressure Study (ANBP2). Clin Exp Pharmacol Physiol 2001;28:663–667.PubMedCrossRefGoogle Scholar
  41. 41.
    Solomon S, Rice M, Jablonski K, Jose P, Domanski M. Renal function and effectiveness of angiotensin converting enzyme inhibitor therapy in patients with stable coronary artery disease in the Prevention of Events with ACE inhibition (PEACE) Trial. Circulation 2006;114:26–31.PubMedCrossRefGoogle Scholar
  42. 42.
    Anderson S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601–606.CrossRefGoogle Scholar
  43. 43.
    Cohn JN, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. The (VALHeFt) Trial. N Engl J Med 2001;345:1667–1675.PubMedCrossRefGoogle Scholar
  44. 44.
    Pitt B, Poole-Wilson PA, Segal R. Effects of Losartan compared with captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study (ELITE II). Lancet 2000;355:1582–1587.PubMedCrossRefGoogle Scholar
  45. 45.
    Chobanian AV, Bakris G, Black HR. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of Hypertension JAMA 2003;289:2560–2571PubMedCrossRefGoogle Scholar
  46. 46.
    Vijan S, et al. Treatment of hypertension in type 2 diabetes mellitus: blood pressue goals, choice of agents and setting priorities in diabetes care. Ann Int Med 2003;138:593–602.PubMedCrossRefGoogle Scholar
  47. 47.
    American Diabetes Association. Hypertension in type-2 diabetes. Diabetes Care 2007;30:S4–S41.CrossRefGoogle Scholar
  48. 48.
    Chobanian AV. Interrelationship of hypertension and type-2 diabetes. Hypertension 2003;42:1206–1252.PubMedCrossRefGoogle Scholar

Supplementary Readings

  1. Bell DSH. Beta-adrenergic blocking agents in patients with diabetes – friend or foe? Endocr Pract 1999;5:51–53.PubMedCrossRefGoogle Scholar
  2. Chirstensen PK, Gall MA, et al. Course of glomerular filtration rate in albuminuric type 2 diabetic patients with or without diabetic glomerulopathy. Diabetes Care 2000;23(Suppl 2):B4–B20.Google Scholar
  3. Cooper M, Johnston C. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000;283(24):3177–3179.PubMedCrossRefGoogle Scholar
  4. Cooper ME, Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998;352:213–219.PubMedCrossRefGoogle Scholar
  5. DeStefano F, Ford ES, et al. Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993:3(1):27–34.PubMedCrossRefGoogle Scholar
  6. Elkeles RS, Diamond JR, et al. Caridovasccular outcomes in type 2 diabetes. Diabetes Care 1992;15:820–825.CrossRefGoogle Scholar
  7. Fu Y, Deedwania P. Management of hypertensive patients with diabetes mellitus. Cin Ger 2001;9(7):22–36.Google Scholar
  8. Factor SM, Minase T, et al. Clinical and Morphological features of human hypertensive diabetic cardiomyopathy. Am Heart J 1980;99:446–458.PubMedCrossRefGoogle Scholar
  9. Giese M, Lackland DT, et al. The hypertension initiative of South Carolina. Promoting cardiovascular health through better blood pressure control. J S C Med Assoc 2001;97:57–62.PubMedGoogle Scholar
  10. Gustaffson I, et al. Effect of the angiotensin converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol 1999;34:83–89.CrossRefGoogle Scholar
  11. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 2001;24:454–459.PubMedCrossRefGoogle Scholar
  12. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.CrossRefGoogle Scholar
  13. Larme AC, Pugh JA, et al. Attitudes of primary care providers toward diabetes: barriers to guideline implementation. Diabetes Care 1998;21:1391–1396.PubMedCrossRefGoogle Scholar
  14. Lazarus JM, Bourgoignie JJ, et al. Achievement and safety of a low BP goal in chronic renal disease. Hypertension 1997;29:641–650.PubMedCrossRefGoogle Scholar
  15. Parving HH, Lehnert H, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878.PubMedCrossRefGoogle Scholar
  16. Pyorala K, Pedersen TR, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease. Diabetes Care 1997;20:614–620.PubMedCrossRefGoogle Scholar
  17. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341(19):1127–1133.PubMedCrossRefGoogle Scholar
  18. Staessen JA, Fagard R, et al. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757–764.PubMedCrossRefGoogle Scholar
  19. Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes Care 1999; 22(Suppl 3):C14–C20.PubMedGoogle Scholar
  20. Sniderman A, Michel C, et al. Heart disease in patients with diabetes mellitus. J Clin Epidemiol 1992;45:1357–1370.PubMedCrossRefGoogle Scholar
  21. Van Hoeven KH, et al. A comparison of the pathological spectrum of hypertensive, diabetic and hypertensive diabetic heart disease. Circulation 1990;82:848–855.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ronald A. Codario
    • 1
  1. 1.University of Pennsylvania Health System Thomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations